Advertisement
Research Article Free access | 10.1172/JCI104908
Department of Internal Medicine, The University of Texas, Southwestern Medical School, Dallas, Texas
†Work done during tenure of U. S. Air Force postdoctoral fellowship. Present address: Department of Medicine, Endocrine-Renal Section, Wilford Hall, U. S. Air Force Hospital, Lackland Air Force Base, San Antonio, Texas.
‡Work done during tenure of U. S. Public Health Service postdoctoral fellowship (APD-17,224) of the National Institute of Arthritis and Metabolic Diseases. Present address: Department of Surgery, The University of Texas, Southwestern Medical School, Dallas, Texas.
*Submitted for publication July 12, 1963; accepted October 17, 1963.
This work was supported in part by a U. S. Public Health Service grant (A-4236) from the National Institute of Arthritis and Metabolic Diseases, Bethesda, Md., and by grants from the Upjohn Co., Kalamazoo, Mich., and Chas. Pfizer & Co., New York, N. Y.
A preliminary report of this work has been published in abstract form (The paradoxical effect of hydrocortisone on hepatic glucose output. Clin. Res. 1961, 9, 29).
Find articles by Lecocq, F. in: JCI | PubMed | Google Scholar
Department of Internal Medicine, The University of Texas, Southwestern Medical School, Dallas, Texas
†Work done during tenure of U. S. Air Force postdoctoral fellowship. Present address: Department of Medicine, Endocrine-Renal Section, Wilford Hall, U. S. Air Force Hospital, Lackland Air Force Base, San Antonio, Texas.
‡Work done during tenure of U. S. Public Health Service postdoctoral fellowship (APD-17,224) of the National Institute of Arthritis and Metabolic Diseases. Present address: Department of Surgery, The University of Texas, Southwestern Medical School, Dallas, Texas.
*Submitted for publication July 12, 1963; accepted October 17, 1963.
This work was supported in part by a U. S. Public Health Service grant (A-4236) from the National Institute of Arthritis and Metabolic Diseases, Bethesda, Md., and by grants from the Upjohn Co., Kalamazoo, Mich., and Chas. Pfizer & Co., New York, N. Y.
A preliminary report of this work has been published in abstract form (The paradoxical effect of hydrocortisone on hepatic glucose output. Clin. Res. 1961, 9, 29).
Find articles by Mebane, D. in: JCI | PubMed | Google Scholar
Department of Internal Medicine, The University of Texas, Southwestern Medical School, Dallas, Texas
†Work done during tenure of U. S. Air Force postdoctoral fellowship. Present address: Department of Medicine, Endocrine-Renal Section, Wilford Hall, U. S. Air Force Hospital, Lackland Air Force Base, San Antonio, Texas.
‡Work done during tenure of U. S. Public Health Service postdoctoral fellowship (APD-17,224) of the National Institute of Arthritis and Metabolic Diseases. Present address: Department of Surgery, The University of Texas, Southwestern Medical School, Dallas, Texas.
*Submitted for publication July 12, 1963; accepted October 17, 1963.
This work was supported in part by a U. S. Public Health Service grant (A-4236) from the National Institute of Arthritis and Metabolic Diseases, Bethesda, Md., and by grants from the Upjohn Co., Kalamazoo, Mich., and Chas. Pfizer & Co., New York, N. Y.
A preliminary report of this work has been published in abstract form (The paradoxical effect of hydrocortisone on hepatic glucose output. Clin. Res. 1961, 9, 29).
Find articles by Madison, L. in: JCI | PubMed | Google Scholar
Published February 1, 1964 - More info